Share
Perspectives
Related articles
Perspectives
First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Bicara Therapeutics
First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
This is some text inside of a div block.
This is some text inside of a div block.
Perspectives
Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023
Bicara Therapeutics
Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023
This is some text inside of a div block.
This is some text inside of a div block.
Perspectives
Announces Oversubscribed $165 Million Series C Financing
Bicara Therapeutics
Announces Oversubscribed $165 Million Series C Financing
This is some text inside of a div block.
This is some text inside of a div block.